论文部分内容阅读
目的:观察硫辛酸联合氟哌噻吨美利曲辛片治疗尿毒症患者不宁腿综合征(RLS)的疗效和安全性。方法:68例维持性血液透析患者随机分为观察组与对照组,分别给予硫辛酸联合氟哌噻吨美利曲辛片治疗及单纯氟哌噻吨美利曲辛片治疗。治疗开始及结束时进行RLS评分,比较两组疗效与药品不良反应差异。结果:观察组总有效率82.85%,对照组总有效率54.54%,差异有统计学意义(P<0.05)。治疗结束时两组RLS评分均较前不同程度下降(P<0.05);且观察组RLS评分较对照组下降更明显(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论:硫辛酸联合氟哌噻吨美利曲辛片可减轻尿毒症患者RLS的临床症状,安全性好,疗效优于单用氟哌噻吨美利曲辛片。
Objective: To observe the efficacy and safety of lipoic acid combined with flupentixol and melitracen tablet in the treatment of restless legs syndrome (RLS) in uremic patients. Methods: Sixty-eight patients with maintenance hemodialysis were randomly divided into observation group and control group. The patients were treated with lipoic acid combined with flupentixol and melitracen tablets and flupentixol and melitracen tablets respectively. The RLS score at the beginning and the end of the treatment was compared between the two groups and the differences between the two groups were compared. Results: The total effective rate was 82.85% in observation group and 54.54% in control group, the difference was statistically significant (P <0.05). At the end of treatment, the RLS scores of both groups decreased to some extent (P <0.05), and the RLS score of the observation group decreased more significantly than that of the control group (P <0.05). Adverse reactions between the two groups, the difference was not statistically significant (P> 0.05). CONCLUSION: Alpha-lipoic acid combined with flupentixol and melitracen tablet can relieve the clinical symptoms of RLS in patients with uremia, which is safe and superior to flupentixol and melitracen tablets alone.